Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.3.1.900
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Nov. 30, 2015
Nov. 30, 2014
Statement of Cash Flows [Abstract]    
Net Income $ 8,106,343 $ 553,623
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 241,208 377,008
Impairment of investment in Saneron 684,000  
Abandonment of patents   25,649
Compensatory element of stock options 602,978 404,233
Provision for doubtful accounts 699,682 1,303,436
Equity in losses of affiliate 18,824 362,884
Deferred income tax benefit (7,369,513)  
Changes in assets and liabilities:    
Accounts receivable 313,936 (2,038,973)
Notes receivable   550,782
Prepaid expenses 178,935 (220,769)
Inventory 117,231  
Other current assets (29,008) 31,858
Deposits and other assets, net 11,243 37,628
Accounts payable 335,709 (201,915)
Accrued expenses (540,246) (329,112)
Deferred revenue 1,480,140 698,489
Net cash provided by operating activities 4,851,462 1,554,821
Cash flows from investing activities:    
Release of restricted cash held in escrow (203) 763,989
Purchases of property and equipment (108,480) (120,517)
Purchase of Prepacyte®-CB (375,374)  
Purchases of marketable securities and other investments, net (235,292) (64,764)
Investment in affiliate   (187,500)
Net cash (used in) provided by investing activities (719,349) 391,208
Cash flows from financing activities:    
Treasury stock purchases (3,205,435) (2,671,060)
Repayments of note payable (123,633)  
Proceeds from the exercise of stock options 69,850 79,142
Net cash used in financing activities (3,259,218) (2,591,918)
Increase (decrease) in cash and cash equivalents 872,895 (645,889)
Cash and cash equivalents - beginning of period 3,279,267 3,925,156
Cash and cash equivalents - end of period 4,152,162 3,279,267
Supplemental non-cash investing activities:    
Unrealized gain on marketable securities 169,932 0
Disposition of Cryo-Cell common stock held by Saneron, increase in investment   $ 81,480
Issuance of note payable in connection with the purchased business 1,300,000  
Assumption of accrued expenses in connection with the purchased business 423,504  
Decrease in prepaid expenses in connection with the purchased business $ 104,000